# Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation

> **NCT01848743** · PHASE3 · UNKNOWN · sponsor: **Kaohsiung Veterans General Hospital.** · enrollment: 120 (estimated)

## Conditions studied

- Chronic HBV With Severe Exacerbation

## Interventions

- **DRUG:** Tenofovir
- **DRUG:** lamivudine

## Key facts

- **NCT ID:** NCT01848743
- **Lead sponsor:** Kaohsiung Veterans General Hospital.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-04
- **Primary completion:** 2016-04
- **Final completion:** 2016-10
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2014-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01848743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01848743, "Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01848743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*